https://scholars.lib.ntu.edu.tw/handle/123456789/477806
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YEN-SHEN LU | en_US |
dc.contributor.author | Chen D.-R. | en_US |
dc.contributor.author | Tseng L.-M. | en_US |
dc.contributor.author | Yeh D.-C. | en_US |
dc.contributor.author | Chen S.-T. | en_US |
dc.contributor.author | Hsieh C.-M. | en_US |
dc.contributor.author | Wang H.-C. | en_US |
dc.contributor.author | Yeh H.-T. | en_US |
dc.contributor.author | SUNG-HSIN KUO | en_US |
dc.contributor.author | CHIUN-SHENG HUANG | en_US |
dc.creator | Lu Y.-S.;Chen D.-R.;Tseng L.-M.;Yeh D.-C.;Chen S.-T.;Hsieh C.-M.;Wang H.-C.;Yeh H.-T.;Kuo S.-H.;Chiun-Sheng Huang | - |
dc.date.accessioned | 2020-03-23T07:19:22Z | - |
dc.date.available | 2020-03-23T07:19:22Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959617879&doi=10.1007%2fs00280-010-1401-2&partnerID=40&md5=76d8b2ca55c6dcd82b1a2d0350853ae9 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/477806 | - |
dc.description.abstract | Purpose: Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies. The purpose of this study was to assess the efficacy of a combination of docetaxel, capecitabine, and cisplatin (TXP) in patients diagnosed with locally advanced breast cancer (LABC). Methods: Patients (n = 42) with chemotherapy-na?ve LABC (stage IIIa or IIIb) were enrolled. The chemotherapeutic regimen consisted of 4-6 cycles of intravenous docetaxel (60 mg/m2) and cisplatin (50 mg/m2) on day 1, plus oral capecitabine (1,800 mg/m2/day) on day 1-14, repeated every 3 weeks. Upon completion of therapy, the primary tumor was resected when not contraindicated. Results: Median patient age was 48.5 years (range 31-66 years). Median tumor size was 6.8 cm (range 2.7-15 cm), 29 patients were node-positive, and 12 patients were hormone receptor positive. A total of 216 cycles (median 5; range 3-6 cycles) were administered without prophylactic G-CSF. The predominant toxicities were grade 3/4 neutropenia (30%/28%) and no grade 3/4 thrombocytopenia, febrile neutropenia, or grade 4 non-hematological toxicities were observed. Grade 3 non-hematological toxicities included hand-foot syndrome (5.6%) and vomiting (0.5%). The overall clinical response rate was 97.6% (41/42). Six of the 42 patients (14.3%) achieved a complete pathological response. Of 22 patients who completed 6 cycles of combination treatment, the complete pathological response was 27.3% (6/22). Conclusions: A combination of TXP can be administered safely without prophylactic G-CSF, and appears to be an effective neoadjuvant regimen in patients with LABC. ? 2010 Springer-Verlag. | - |
dc.relation.ispartof | Cancer Chemotherapy and Pharmacology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | capecitabine; cisplatin; docetaxel; granulocyte colony stimulating factor; hormone receptor; adult; advanced cancer; aged; alopecia; anemia; article; breast cancer; cancer adjuvant therapy; cancer combination chemotherapy; cancer size; clinical article; diarrhea; drug efficacy; edema; female; fever; hand foot syndrome; human; infection; leukopenia; lymph node metastasis; multicenter study; multiple cycle treatment; nail; nausea; nephrotoxicity; neurotoxicity; neutropenia; phase 2 clinical trial; priority journal; prospective study; side effect; stomatitis; thrombocytopenia; treatment response; vomiting; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prospective Studies; Taxoids | - |
dc.title | Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s00280-010-1401-2 | - |
dc.identifier.pmid | 20700740 | - |
dc.identifier.scopus | 2-s2.0-79959617879 | - |
dc.relation.pages | 1257-1263 | - |
dc.relation.journalvolume | 67 | - |
dc.relation.journalissue | 6 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Clinical Trial Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiation Oncology-NTUCC | - |
crisitem.author.dept | Division of Radiation Oncology | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.orcid | 0000-0001-7461-1291 | - |
crisitem.author.orcid | 0000-0003-0054-887X | - |
crisitem.author.orcid | 0000-0002-6557-211X | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | Oncology-NTUH | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。